Biosimilar Naming: How Could the Suffix Impact the U.S. Health System?

Wednesday, February 27, 2019
Presented by: 
Eric Henry

Eric Henry, Clinical Content Specialist focused on the domestic drug file with Clinical Effectiveness at Wolters Kluwer, Heath, in a 45-minute live webinar to discuss: 

  • The potential impact of biosimilars at this tipping point in the pharmaceutical industry 
  • FDA-required suffixes and standards for biosimilars naming 
  • Prescription workflow best practices for small and large molecule biosimilars 
  • Issues raised by retrospective naming and products without suffixes 

The RxPerts Academy from Wolters Kluwer wants to help you better understand the impact of biosimilar naming conventions. Despite their potential to save the U.S. healthcare system billions of dollars, the widespread adoption of biosimilars has been slow, due to complexities in approving, naming, standardizing, and reporting on these new products.

You may also like:

Blog Post

It has been exciting for me to relive the successful mission of Apollo 11 to the moon on July 20, 1969. Were you alive on that summer day when histo...

View Blog Post
Blog Post

Patient education has become a key element of the patient care and treatment experience. Whether at office visits, in care settings, or through patient portals, distributing information on conditions, medications, and follow-up...

View Blog Post
Blog Post

Everyday there are more news headlines about policymakers addressing different approaches to lowering healthcare and prescription drug costs. This spring alone saw news about the

View Blog Post

Filter by Type

Sign up to receive the latest news and information!

Sign Up